Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Invested Capital (2016 - 2025)

Historic Invested Capital for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $433.5 million.

  • Adma Biologics' Invested Capital rose 8695.5% to $433.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $433.5 million, marking a year-over-year increase of 8695.5%. This contributed to the annual value of $349.0 million for FY2024, which is 15813.8% up from last year.
  • As of Q3 2025, Adma Biologics' Invested Capital stood at $433.5 million, which was up 8695.5% from $398.3 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Invested Capital registered a high of $433.5 million during Q3 2025, and its lowest value of $100.4 million during Q3 2022.
  • Over the past 5 years, Adma Biologics' median Invested Capital value was $146.8 million (recorded in 2023), while the average stood at $193.1 million.
  • As far as peak fluctuations go, Adma Biologics' Invested Capital tumbled by 1103.35% in 2023, and later soared by 15813.8% in 2024.
  • Over the past 5 years, Adma Biologics' Invested Capital (Quarter) stood at $141.2 million in 2021, then increased by 7.65% to $152.0 million in 2022, then dropped by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024, then increased by 24.21% to $433.5 million in 2025.
  • Its Invested Capital was $433.5 million in Q3 2025, compared to $398.3 million in Q2 2025 and $373.4 million in Q1 2025.